{"id":2063,"date":"2017-04-19T11:28:17","date_gmt":"2017-04-19T11:28:17","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=2063"},"modified":"2024-09-18T15:35:56","modified_gmt":"2024-09-18T10:05:56","slug":"the-snippet-targeting-metabolism-in-renal-cell-carcinoma","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/the-snippet-targeting-metabolism-in-renal-cell-carcinoma","title":{"rendered":"The Snippet: Targeting metabolism in Renal Cell Carcinoma"},"content":{"rendered":"<p style=\"text-align: justify;\">Loss of VHL and elevated expression of HIF transcription factors leads to reprogramming of tumour cell metabolism, enabling renal cell carcinoma (RCC) cells to use carbons from glutamine-derived aspartate to drive pyrimidine biosynthesis. Now, researchers show that inhibition of glutamine availability decreases aspartate availability, leading to growth inhibition of RCC cells. Moreover, glutaminase\u00a01 (GLS1) inhibition increases oxidative stress, leading to DNA replication stress and growth arrest. \u201cThese findings led us to combine a GLS1 inhibitor with an inhibitor of DNA repair enzymes \u2014 in this case, a poly(ADPribose) polymerase (PARP) inhibitor \u2014 to achieve therapeutic synergism,\u201d explains Othon Iliopoulos. \u201cIn other words, we discovered how targeting a metabolic pathway renders VHL-deficient cancer cells sensitive to DNA repair mechanisms.\u201d Iliopoulos hopes to take their findings directly to a clinical trial. \u201cWe now plan to treat patients with renal and other HIF-expressing cancers with this novel combination of GLS1 and PARP inhibitors,\u201d he explains.<\/p>\n<p style=\"text-align: justify;\">To know more, click <a href=\"https:\/\/www.nature.com\/nrneph\/journal\/vaop\/ncurrent\/full\/nrneph.2017.57.html\">Renal Cell Carcinoma<\/a>.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Loss of VHL and elevated expression of HIF transcription factors leads to reprogramming of tumour cell metabolism, enabling renal cell carcinoma (RCC) cells to use carbons from glutamine-derived aspartate to drive pyrimidine biosynthesis. Now, researchers show that inhibition of glutamine availability decreases aspartate availability, leading to growth inhibition of RCC cells. Moreover, glutaminase\u00a01 (GLS1) inhibition [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":698,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[41],"tags":[1771,634,856,855,854,739],"industry":[17225],"therapeutic_areas":[17228],"class_list":["post-2063","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-snippets","tag-cancers","tag-drug-development","tag-hif-expressing-cancers","tag-parp-inhibitors","tag-renal-cell-carcinoma","tag-snippet","industry-pharmaceutical","therapeutic_areas-oncology"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Spotlight: Disrupting Metabolic Processes in Renal Cell Carcinoma<\/title>\n<meta name=\"description\" content=\"Loss of VHL and elevated expression of HIF transcription factors leads to reprogramming of tumour cell metabolism, enabling RCC cells\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/the-snippet-targeting-metabolism-in-renal-cell-carcinoma\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Spotlight: Disrupting Metabolic Processes in Renal Cell Carcinoma\" \/>\n<meta property=\"og:description\" content=\"Loss of VHL and elevated expression of HIF transcription factors leads to reprogramming of tumour cell metabolism, enabling RCC cells\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/the-snippet-targeting-metabolism-in-renal-cell-carcinoma\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2017-04-19T11:28:17+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-09-18T10:05:56+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2015\/10\/06175102\/lung-cancer-cells-dividing2.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"640\" \/>\n\t<meta property=\"og:image:height\" content=\"225\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"DelveInsight\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"DelveInsight\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Spotlight: Disrupting Metabolic Processes in Renal Cell Carcinoma","description":"Loss of VHL and elevated expression of HIF transcription factors leads to reprogramming of tumour cell metabolism, enabling RCC cells","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/the-snippet-targeting-metabolism-in-renal-cell-carcinoma","og_locale":"en_US","og_type":"article","og_title":"Spotlight: Disrupting Metabolic Processes in Renal Cell Carcinoma","og_description":"Loss of VHL and elevated expression of HIF transcription factors leads to reprogramming of tumour cell metabolism, enabling RCC cells","og_url":"https:\/\/www.delveinsight.com\/blog\/the-snippet-targeting-metabolism-in-renal-cell-carcinoma","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2017-04-19T11:28:17+00:00","article_modified_time":"2024-09-18T10:05:56+00:00","og_image":[{"width":640,"height":225,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2015\/10\/06175102\/lung-cancer-cells-dividing2.jpg","type":"image\/jpeg"}],"author":"DelveInsight","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"DelveInsight","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/the-snippet-targeting-metabolism-in-renal-cell-carcinoma","url":"https:\/\/www.delveinsight.com\/blog\/the-snippet-targeting-metabolism-in-renal-cell-carcinoma","name":"Spotlight: Disrupting Metabolic Processes in Renal Cell Carcinoma","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/the-snippet-targeting-metabolism-in-renal-cell-carcinoma#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/the-snippet-targeting-metabolism-in-renal-cell-carcinoma#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2015\/10\/06175102\/lung-cancer-cells-dividing2.jpg","datePublished":"2017-04-19T11:28:17+00:00","dateModified":"2024-09-18T10:05:56+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a"},"description":"Loss of VHL and elevated expression of HIF transcription factors leads to reprogramming of tumour cell metabolism, enabling RCC cells","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/the-snippet-targeting-metabolism-in-renal-cell-carcinoma"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/the-snippet-targeting-metabolism-in-renal-cell-carcinoma#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2015\/10\/06175102\/lung-cancer-cells-dividing2.jpg","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2015\/10\/06175102\/lung-cancer-cells-dividing2.jpg","width":640,"height":225},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a","name":"DelveInsight","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","caption":"DelveInsight"}}]}},"author_meta":{"display_name":"DelveInsight","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/gtadmin"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2015\/10\/06175102\/lung-cancer-cells-dividing2-300x105.jpg","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">Snippets - A Small piece of News or Article<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Snippets - A Small piece of News or Article<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">cancers<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">drug development<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">HIF-expressing cancers<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">PARP inhibitors<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">Renal Cell Carcinoma<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">Snippet<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">cancers<\/span>","<span class=\"advgb-post-tax-term\">drug development<\/span>","<span class=\"advgb-post-tax-term\">HIF-expressing cancers<\/span>","<span class=\"advgb-post-tax-term\">PARP inhibitors<\/span>","<span class=\"advgb-post-tax-term\">Renal Cell Carcinoma<\/span>","<span class=\"advgb-post-tax-term\">Snippet<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 9 years ago","modified":"Updated 2 years ago"},"absolute_dates":{"created":"Posted on Apr 19, 2017","modified":"Updated on Sep 18, 2024"},"absolute_dates_time":{"created":"Posted on Apr 19, 2017 11:28 am","modified":"Updated on Sep 18, 2024 3:35 pm"},"featured_img_caption":"","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/2063","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=2063"}],"version-history":[{"count":1,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/2063\/revisions"}],"predecessor-version":[{"id":29647,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/2063\/revisions\/29647"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/698"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=2063"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=2063"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=2063"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=2063"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=2063"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}